ABSI — Absci Corp

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1672688 ·
Last close
$9.63
Market Cap
$1.65B
52W High
$12.06
52W Low
$5.08
ADV30
2,870,994
Next earnings
2026-11-16
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 215,000 -30,846,000 -29,599,000 195,593,000 8,627,000 23,622,000
Dec 2025 650,000 -36,142,000 -29,562,000 216,297,000 20,025,000 26,848,000
Sep 2025 378,000 -30,154,000 -28,706,000 244,992,000 9,476,000 34,652,000
Jun 2025 593,000 -31,393,000 -30,569,000 209,892,000 38,024,000 36,519,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-97,393,000
Investing CF
$-27,754,000
Financing CF
$70,711,000
CapEx
$-1,240,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.83
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-654,383,000
Inventory
Receivables
$1,000,000
ST Investments
$117,078,000
EBIT TTM
$-118,197,000
Pretax Income TTM
$-118,345,000
Interest Exp TTM
$148,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,561,000
EBITDA
$-119,506,000
Free Cash Flow
$-50,591,752
Enterprise Value
$1,455,329,920
Total Cash
$201,142,000
Total Debt
$3,829,000
Shares Out
171,614,010
Trailing EPS
$-0.86
Book Value
$1.44
ROE
-57.7%
ROA
-34.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,800,000 -125,418,000 -115,183,000 216,297,000 26,848,000 -92,925,000
Dec 2024 4,534,000 -108,888,000 -103,106,000 213,608,000 34,475,000 -72,402,000
Dec 2023 5,718,000 -94,180,000 -110,566,000 217,298,000 41,122,000 -64,636,000
Dec 2022 5,747,000 -106,750,000 -104,904,000 321,008,000 46,594,000 -81,339,000

TTM Snapshot

Revenues TTM
$1,701,000
NetIncome TTM
$-27,398,000
OpCashFlow TTM
$0
Assets (Latest)
$213,608,000
Forward EPS
$-0.68

Max Pain — expiry 2026-11-20

max pain strike: $6.00 · spot: $9.19 · call oi: 12,896 · put oi: 1,143
Expected Move to 2026-11-20: ±$4.10 (44.59%) — implied range $5.09$13.29 · ATM straddle on $9.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NTLA Intellia Therapeutics, Inc. $1.89B $13.51
NEOG NEOGEN CORP $2.54B $11.64
QDEL QuidelOrtho Corp $1.03B $15.05
CLDX Celldex Therapeutics, Inc. $3.24B $41.22
ACHV ACHIEVE LIFE SCIENCES, INC. $840.71M $8.17

News headlines (Yahoo Finance, 1h cache)

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
2026-08-18 07:43 · Yahoo
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation
2026-08-12 17:11 · Yahoo
Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?
2026-08-12 07:10 · Yahoo
Absci Q2 Earnings Call Highlights
2026-08-11 22:04 · Yahoo
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
2026-08-11 20:05 · Yahoo
Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
2026-07-30 13:40 · Yahoo
AMD’s $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
2026-08-18 21:07 · Yahoo
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
2026-08-17 13:56 · Yahoo
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
2026-08-17 05:01 · Yahoo
Absci Corporation Q2 2026 Earnings Call Summary
2026-08-12 00:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.